2019 American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU 2019)

First-line avelumab + axitinib tops sunitinib for advanced RCC

Roshini Claire Anthony, 20190313140203

Patients with renal cell carcinoma (RCC) who received the first-line combination of avelumab and axitinib had longer progression-free survival (PFS) compared with those who received sunitinib, particularly those with PD-L1–positive tumours, according to findings of the phase III JAVELIN Renal 101* trial.

Darolutamide + ADT: A dynamic duo for nmCRPC?

Roshini Claire Anthony, 20190308140206

Men with nonmetastatic castration-resistant prostate cancer (nmCRPC) more than halved their risk of dying or developing distant metastasis when treated with darolutamide in addition to androgen deprivation therapy (ADT), according to findings of the phase III ARAMIS* trial.

Sacituzumab govitecan shows promise in advanced bladder cancer

Pearl Toh, 20190307190010

Sacituzumab govitecan, a novel investigational antibody-drug conjugate, showed clinical activity in patients with metastatic urothelial carcinoma (mUC) who had progressed following standard therapy, including treatment with checkpoint inhibitors, according to an early study presented at GUCS 2019.

Pembrolizumab + axitinib: Potential SOC for advanced clear-cell RCC?

Roshini Claire Anthony, 20190305140302

The combination of pembrolizumab and axitinib in the first-line setting yielded superior survival outcomes compared with sunitinib in patients with advanced renal cell carcinoma (RCC), according to results of the phase III KEYNOTE-426* trial.

Vofatamab shows promise in urothelial cancer

Audrey Abella, 20190228100000

The experimental drug vofatamab, a fibroblast growth factor receptor 3 (FGFR3) targeted antibody, exhibited a favourable safety profile when used alone or in combination with the chemotherapeutic agent docetaxel in patients with metastatic urothelial carcinoma (mUC), according to the results of the FIERCE-21* trial presented at ASCO GU 2019.

Tivozanib outdoes sorafenib in RCC in TIVO-3

Audrey Abella, 20190227100000

The biochemically potent, highly selective VEGFR TKI* tivozanib trumped sorafenib in improving progression-free survival (PFS) and objective response rate (ORR) in patients with refractory advanced renal cell carcinoma (RCC), according to results of the TIVO-3** study presented at ASCO GU 2019.

CheckMate 214: Sustained OS benefit with frontline nivolumab/ipilimumab in RCC

Pearl Toh, 20190226190010

A combination therapy of nivolumab plus ipilimumab (NIVO + IPI) continues to confer survival benefit and durable response over 30 months of follow-up compared with sunitinib in patients with advanced renal cell carcinoma (RCC), according to updated results of CheckMate 214 presented at ASCO Genitourinary Cancers Symposium (GUCS) 2019.

Enzalutamide plus ADT improves outcomes in metastatic hormone-sensitive prostate cancer

Christina Lau, 20190221041931

Enzalutamide in combination with androgen deprivation therapy (ADT) is shown to improve outcomes vs ADT alone in men with metastatic hormone-sensitive prostate cancer in the phase III ARCHES trial.